



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Doxifluridine-d<sub>2</sub>

|                    |                                                                                           |
|--------------------|-------------------------------------------------------------------------------------------|
| Cat. No.:          | HY-B0021S                                                                                 |
| CAS No.:           | 84258-25-3                                                                                |
| Molecular Formula: | C <sub>9</sub> H <sub>9</sub> D <sub>2</sub> FN <sub>2</sub> O <sub>5</sub>               |
| Molecular Weight:  | 248.2                                                                                     |
| Target:            | Nucleoside Antimetabolite/Analog                                                          |
| Pathway:           | Cell Cycle/DNA Damage                                                                     |
| Storage:           | Please store the product under the recommended conditions in the Certificate of Analysis. |



### BIOLOGICAL ACTIVITY

|             |                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Description | Doxifluridine-d <sub>2</sub> is the deuterium labeled Doxiluridine[1]. Doxiluridine is a thymidine phosphorylase activator for PC9-DPE2 cells with IC50 of 0.62 μM.                                                                                                                                                                                                                                                            |
| In Vitro    | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

### REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019 Feb;53(2):211-216.
- [2]. Dipartimento di Chimica, Università degli Studi della Basilicata, Potenza, In vitro toxicity of N3-methyl-5'-deoxy-5-fluorouridine, a novel metabolite of doxiluridine: a bioanalytical investigation. *J Pharm Biomed Anal*. 1998 May;17(1):11-6.
- [3]. Baek IH, Lee BY, Kim MS, Pharmacokinetic analysis of doxiluridine and its metabolites, 5-fluorouracil and 5-fluorouridine, after oral administration in beagle dogs. *Eur J Drug Metab Pharmacokinet*. 2013 Apr 7.
- [4]. Yoshikawa T, Tsuburaya A, Shimada K, A phase II study of doxiluridine and docetaxel combination chemotherapy for advanced or recurrent gastric cancer. *Gastric Cancer*. 2009;12(4):212-8.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA